Cryofocus Medtech (Shanghai) Co., Ltd. announced that, on January 3, 2024, the company has passed the Good Manufacturing Practice (GMP) examination conducted by the Shanghai Medical Products Administration (Shanghai) Administration (Shanghai) Co., Ltd. (Shanghai) Co. Ltd. (AF Cryoablation System). The examination result has proved that the Company has good GMP for medical devices, and at the same time, the passing of the aforesaid examination marks a solid step of the company towards commercialization of the AF Cryoablation System.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.97 HKD | -1.55% | -10.64% | -62.96% |
03-27 | Cryofocus Medtech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-15 | Cryofocus Medtech Gets Marketing Approval in China for Cryoadhesion System | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-62.96% | 217M | |
+37.78% | 705B | |
+32.82% | 583B | |
-3.51% | 364B | |
+19.94% | 332B | |
+5.14% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.32% | 169B |
- Stock Market
- Equities
- 6922 Stock
- News Cryofocus Medtech (Shanghai) Co., Ltd.
- Cryofocus Medtech Co., Ltd. Obtains Approval for Manufacturing Its Atrial Fibrillation Cryoablation System